Call Our HELPLINE: 1-800-4PD-INFO (473-4636)

Should Patients and Families Be Considering Tasigna (Nilotinib) Therapy for Parkinson’s Disease? The NPF Recommends Further Study but Not Clinical Use of this Investigational Drug

Tasigna (Nilotinib) is a leukemia drug that has recently been tested for safety in a small, phase I clinical trial on about a dozen Parkinson’s disease patients. The study had positive results that certainly warrant the continuation to a phase II trial, however it is too early for patients to seek treatment outside the setting of a clinical trial A research study in humans that aims to test a new intervention – this could be a drug, surgery or therapy like exercise or diet guidelines – to make sure it is effective and safe.. The study was very small, and it was not placebo controlled. The clinical trial process was designed primarily around patient safety, which is a critical issue with a chemotherapy drug, and this process should continue and more systematic evidence needs to be collected before we can truly understand the impact of this drug.

If you are interested in learning more about the results of this clinical trial, visit Georgetown University National Parkinson Foundation Center of Excellence.  To learn about other clinical trials, check clinical trials.gov for trials taking place in your area.

 

You can find out more about NPF's National Medical Director, Dr. Michael S. Okun, by also visiting the NPF Center of Excellence, University of Florida Health Center for Movement Disorders and Neurorestoration. Dr. Okun is also the author of the Amazon #1 Parkinson's Best Seller 10 Secrets to a Happier Life and 10 Breakthrough Therapies for Parkinson's Disease.

Wednesday, October 21, 2015
New Study Shows 1.2 Million People in the United States Estimated to be Living with Parkinson’s Disease by 2030
Tuesday, July 10, 2018

Parkinson’s Foundation Reveals Most Comprehensive Estimate of
Parkinson’s Prevalence in North America since the 1970’s

Parkinson’s Foundation Elects Howard D. Morgan Chairman of the Board
Tuesday, June 26, 2018

MIAMI & NEW YORK — June 26, 2018 — The Parkinson’s Foundation today announced the election of Howard D. Morgan as chairman of its board of directors. Mr. Morgan, who previously served as the Vice Chair of the nonprofit organization’s board, is a Partner and the Senior Managing Director of Argand Partners in New York.

Parkinson’s Foundation Announces Five New Members of its People with Parkinson’s Advisory Council
Wednesday, June 13, 2018

NEW YORK & MIAMI — June 13, 2018 — The Parkinson’s Foundation today announced five new members of its People with Parkinson’s Advisory Council.

The Parkinson’s Foundation 2018 Gala in New York City Tuesday, May 8, 2018
Monday, May 14, 2018

The Parkinson’s Foundation 2018 Gala was held at Cipriani 25 Broadway in New York City on Tuesday, May 8, 2018.

Parkinson’s Foundation Adds Alison Herman to its Board of Directors
Tuesday, May 8, 2018

MIAMI – May 9, 2018 – The Parkinson’s Foundation today announced the election of Alison Herman to its board of directors. Herman is senior counsel at Southern Glazer’s Wine & Spirits, a company which has generously supported Parkinson’s Foundation fundraisers.

Statement on Nuplazid Drug
Tuesday, April 10, 2018

On 4/9/18, CNN published an article on the FDA-approved drug, Nuplazid, used to treat hallucinations and psychosis in Parkinson’s disease. The article investigates FDA data showing the number of reported deaths with people taking Nuplazid. Nuplazid was approved by the FDA in 2016 and is manufactured by Acadia Pharmaceuticals.

Parkinson’s Foundation Adds John D. Thomopoulos to its Board of Directors
Monday, March 19, 2018

MIAMI & NEW YORK – March 19, 2018 – The Parkinson’s Foundation today announced the election of John D. Thomopoulos to its board of directors. Thomopoulos is a partner at Ernst & Young.

In Memory of Edythe Kay Marsa
Monday, March 12, 2018

The Parkinson’s Foundation mourns the loss of emeritus board member, Edythe (Edy) Kay Marsa. From 1993 to 2014, she was a member of the Foundation’s board of directors and served on several committees. Edy is survived by her husband William Marsa, who founded the Herbert Kay Parkinson Chapter in honor of her first husband who passed away due to complications from Parkinson’s disease.

Parkinson’s Foundation Announces New Genetic Initiative Connecting Parkinson’s Genetic Data with Clinical Care
Tuesday, March 6, 2018

MIAMI & NEW YORK—March 6, 2018—The Parkinson’s Foundation today announced a new initiative offering genetic testing and counseling to Parkinson’s patients within its Center of Excellence network.

Delegates From The Parkinson’s Community Converge On Capitol Hill To Advocate For Critical Research Funding
Monday, March 5, 2018

—2018 Parkinson’s Policy Forum Co-Sponsored by the Parkinson’s Foundation and the Michael J. Fox Foundation for Parkinson’s Research—

Pages

mail icon

Subscribe to get the latest news on treatments, research and other updates.